Q3 2025 Recap: Revenue +23% with 3rd Consecutive Guide Raise, dV5 First OUS Placements — Maintaining Outperform
Key Takeaways
- Q3 revenue $2.51B (+23% YoY, +23% CC) beat Street ~$2.36B by ~$150M — the strongest revenue beat in 6 quarters. da Vinci procedures +19% (accelerating from Q2's +17%); total procedures +20%; SP procedures +91%; Ion +52%. Pro forma EPS $2.40 ($2.28 ex tax benefits) vs Street $2.16 — operational beat $0.12 + US tax reform benefit $0.12 + reserve release. Operating margin 39% sustained.
- 3rd consecutive FY25 guide raise — best multi-quarter raising pattern in years. da Vinci procedure growth 17-17.5% (from 15.5-17%); pro forma GM 67-67.5% (from 66-67%); tariff impact 70bp (from 100bp); pro forma tax rate 21-22% (LOWERED from 22-23% on US tax reform R&D treatment + tax reserve releases). Operating leverage compounding across the year.
- dV5 international launch crossed key milestone — first 12 OUS placements in Japan + Europe; total dV5 installed base 929 globally. In US, 18 of 20 largest IDNs have dV5; 21 fully standardized. Trade-ins 141 (vs 38 YoY, +271%). SP nipple-sparing mastectomy + general surgery regulatory submissions completed. First commercial Ion sales in Australia + Korea.
- US da Vinci utilization +4% (best in years) — driven by dV5 efficiency gains (autonomy, insufflation integration, force feedback). OUS utilization +8% accelerating from prior +4%. The utilization inflection alongside placement growth is the structural compounder pattern. Force feedback clinical evidence mounting across thoracic + colorectal.
- Rating: Maintaining Outperform. Stock +5.5% to ~$501. The print reinforces every component of the multi-quarter compounder thesis: durable procedure growth, accelerating utilization, dV5 mix-up, OUS expansion, accelerated capital return ($1.9B Q3 buyback at ~$475 avg). PT range updated Base $640 / Bull $720 / Bear $500.
Results vs. Consensus
Q3 2025 is the cleanest beat-and-raise of 2025 to date. Revenue +23% accelerated from Q2's +21%; procedure growth +19% accelerated from +17%; operating margin sustained at 39% despite GM headwinds. The 3rd consecutive FY25 guide raise is unprecedented in ISRG's recent history and signals management's growing confidence in the multi-quarter trajectory.
| Metric | Q3 Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Revenue | $2.51B (+23%) | $2.36B | Beat | +$150M / +6.4% |
| da Vinci Procedures | +19% | ~+17% | Beat | +200bp |
| System Placements | 427 (+13%) | ~395 | Beat | +32 |
| Pro Forma Gross Margin | 68.0% | ~67.0% | Beat | +100bp |
| Pro Forma Op Margin | 39% | ~37% | Beat | +200bp |
| Pro Forma EPS (reported) | $2.40 (+30%) | $2.16 | Beat | +$0.24 |
| Pro Forma EPS (ex-tax benefits) | $2.28 | $2.16 | Beat | +$0.12 |
YoY View
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | $2.51B | $2.04B | +23% |
| da Vinci Procedures | +19% | +18% | Accelerating |
| System Placements | 427 | 379 | +13% |
| Pro Forma EPS | $2.40 | $1.84 | +30% |
| Pro Forma Gross Margin | 68.0% | 69.1% | -110bp |
| Cash + Investments | $8.4B | $7.8B | +8% |
QoQ View
| Metric | Q3 2025 | Q2 2025 | QoQ |
|---|---|---|---|
| Revenue | $2.51B | $2.44B | +2.9% |
| System Placements | 427 | 395 | +8.1% |
| Trade-ins | 141 | 83 | +70% |
| dV5 Placements | 240 | 180 | +33% |
| Pro Forma GM | 68.0% | 67.9% | +10bp |
Revenue Assessment
Revenue +23% YoY with procedure growth +20% — both accelerating from Q2. Composition: US procedures +18% (US da Vinci +16%, Ion +48%); OUS procedures +25% (da Vinci +24%, Ion 4x from small base). The US da Vinci utilization +2% reflects mix shift to higher-utilization dV5 platforms. OUS utilization +8% accelerating shows multi-specialty + India/Korea/distributor markets compounding. da Vinci I&A revenue per procedure $1,800 flat (stable pricing despite mix shifts). dV5 ASP rose to $1.6M from $1.5M on higher dual-console mix.
Margin Assessment
Pro forma gross margin 68.0% (-110bp YoY) — compression narrowed vs Q2's -210bp. Drivers: 90bp tariff impact + higher facility costs + dV5/Ion mix + dV5 service costs, partially offset by cost reductions. The Q3 tariff impact better than expected on US-China bilateral reduction. Pro forma operating margin 39% sustained with OpEx +11% (vs revenue +23%) = ~12 percentage points of fixed-cost leverage. Tax rate 18.3% benefited from US tax reform R&D treatment + $16M discrete release; ex-benefits run-rate ~22% (in line with prior).
EPS Assessment
Pro forma EPS $2.40 reported (+30%) / $2.28 ex-tax benefits (+24%). Operational growth +24% on revenue +23% — modest leverage. The $0.12 ex-tax benefit beat is operationally driven. Reported EPS includes $16M tax reserve release ($0.04) + US tax reform R&D benefit ($0.08). Q3 buyback $1.9B (4M shares at avg ~$475) — meaningful acceleration vs Q2's $181M. The pace + price-discipline supports forward EPS leverage.
Segment Performance
da Vinci — $2.0B+ Combined Revenue; +19% Procedure Growth
da Vinci procedures +19% YoY (US +16%; OUS +24%). System placements 427 (+13% from 379) with 240 dV5 (12 OUS — first Japan + Europe placements). Installed base 929 dV5 systems globally. In US, 18 of 20 largest IDNs have dV5; 21 fully standardized. Trade-ins 141 (vs 38 YoY) demonstrating accelerating Xi → dV5 upgrade cycle. dV5 system ASP $1.7M; utilization +2% US, +8% OUS.
Assessment: dV5 OUS launch is the key Q3 strategic milestone. The first 12 OUS placements (Japan + Europe) demonstrate platform-readiness for international scaling. IDN standardization at scale (21 hospitals fully dV5) creates large multi-year I&A + service revenue runway.
Ion — $38K Procedures (+52%); Intentional Placement Discipline
Ion procedures ~38K (+52% YoY) — sustained 50%+ growth. System placements 50 (vs 58 YoY) — intentional restraint. Utilization +14%. First commercial sales in Australia + Korea. Mayo Clinic 2,000-patient study published demonstrating diagnostic yield 79%.
Assessment: Ion economics compounding through utilization not placements. The placement restraint + utilization acceleration is the right strategy for AI-enabled platform.
SP — Single-Port; +91% Procedures
SP procedures +91% YoY with Korea-led strength + Europe/Japan early growth. System placements 30 (vs 21 YoY). Utilization +35%. Nipple-sparing mastectomy + general surgery US regulatory submissions completed.
Assessment: SP continues to be the long-term optionality. US regulatory path expanding TAM materially.
Key Topics & Management Commentary
Overall Management Tone: Most confident of 2025 to date. Revenue acceleration + utilization expansion + dV5 OUS milestones combined with 3rd consecutive guide raise signals management visibility improvement.
1. dV5 First OUS Placements (Japan + Europe)
First 12 dV5 systems placed OUS in Q3 — Japan + Europe markets following recent clearances. Installed base 929 globally. Customer feedback positive.
"Internationally, we placed our first nine systems in Japan and Europe and have received positive early feedback." — David Rosa, CEO
Assessment: OUS dV5 launch is multi-year tailwind. Japan + Europe represent ~30% of global da Vinci TAM.
2. US da Vinci Utilization Acceleration to +4%
US utilization +4% in Q3 vs flat in H1 2025 and +2% prior year. Drove by dV5 efficiency gains + 90% of dV5 procedures using integrated insufflation.
"Da Vinci utilization in the US increased 2% in Q3 compared to flat utilization in the first half of this year and 2% growth last year." — Jamie Samath, CFO
Assessment: Utilization inflection is the structural compounder signal. dV5 efficiency gains compound across all installed-base hospitals over multi-year period.
3. Trade-In Acceleration to 141 (+271% YoY)
Trade-ins 141 vs 38 YoY = 271% increase. Some customers shifting budgets from new system purchases to upgrades.
Assessment: Trade-in cycle in mid-flight. Multi-year runway as Xi installed base of ~10K systems converts to dV5.
4. 3rd Consecutive FY25 Guide Raise
Procedure growth 17-17.5% (3rd raise); GM 67-67.5% (3rd raise); tariff 70bp (2nd reduction); tax rate 21-22% (lowered). Most-aggressive multi-quarter raising pattern in 5+ years.
Assessment: Management visibility improving sharply. FY25 likely lands at high end of all ranges + potential upside.
5. US Tax Reform Impact
US tax reform R&D expense treatment + $16M discrete tax reserve release = ~$0.12 EPS benefit. Forward implications still being evaluated.
Assessment: Tax reform is sustained tailwind not one-time benefit. FY26 tax rate likely settles in 21-22% range.
6. Q3 Buyback $1.9B (4M shares)
$1.9B Q3 buyback at avg ~$475 — meaningful acceleration vs Q2's $181M. Cash + investments declined to $8.4B from $9.5B.
Assessment: Opportunistic buyback at depressed prices. The 4M share reduction is +0.6% of share count — multiple quarters at this pace compound to +2-3% annual EPS leverage.
7. Force Feedback Clinical Evidence Building
Multiple clinical publications across thoracic + colorectal demonstrating force reduction. Ohio State 400-procedure thoracic study showed 20% peak force reduction with FF medium/high settings.
Assessment: Force feedback is dV5's most-differentiated technical feature. Clinical evidence base building over time creates durable competitive moat.
8. SP Regulatory Submissions (NSM + Gen Surg)
Nipple-sparing mastectomy + general surgery US regulatory submissions completed. SP TAM expansion gating mechanism in motion.
Assessment: SP US TAM ramp depends on these clearances. Multi-quarter approval path.
9. Going Direct in Italy, Spain, Portugal
Acquisition of distributor business in Italy/Spain/Portugal targeted for H1 2026. ~250 employee transfer. OUS direct strategy expansion.
Assessment: Going direct improves margin economics + customer relationships. Initial drag on OpEx; benefit emerges 2026-2027.
10. SP and Ion Margin Improvement
dV5 contribution margins approaching Xi levels; Ion approaching corporate average. Multi-year engineering work paying off.
Assessment: Platform-mix margin headwinds easing. FY26 GM should benefit from continued platform margin improvements.
Guidance & Outlook
| Metric | 2025 Updated (Q3) | 2025 Prior (Q2) | Change |
|---|---|---|---|
| da Vinci Procedure Growth | 17-17.5% | 15.5-17% | Raised (3rd consecutive) |
| Pro Forma Gross Margin | 67-67.5% | 66-67% | Raised 100bp |
| Tariff Impact | 70bp +/- 10bp | 100bp +/- 20bp | Reduced |
| Pro Forma OpEx Growth | 11-13% | 10-14% | Tightened |
| Pro Forma Tax Rate | 21-22% | 22-23% | Lowered |
Analyst Q&A Highlights
OUS dV5 Launch Trajectory
Q: "First OUS dV5 placements completed. How does the European + Japan launch trajectory compare to the US, and when does OUS dV5 mix-up become material?"
— Larry Biegelsen, Wells Fargo
A: "Internationally, da Vinci placements reflected ongoing external dynamics in Japan, China, and the UK, offset by broad-based strength in other international markets... We look forward to engaging customers as they continue to evaluate da Vinci V."
— David Rosa, CEO
Assessment: OUS dV5 ramp will be measured. Multi-year impact on OUS ASP + I&A.
Tax Rate Forward Trajectory
Q: "Tax rate dropped to 18.3% Q3. What's the forward run-rate ex one-time benefits?"
— Robbie Marcus, JPMorgan
A: "Our pro forma effective tax rate for quarter three was 18.3%, lower than our expectations, reflecting the impact of the new US tax provisions for the treatment of R&D expenses and a $16 million discrete benefit from the release of tax reserves... we are still evaluating potential impacts of US tax reform for our 2026 tax rate."
— Jamie Samath, CFO
Assessment: Forward run-rate likely 21-22% (the new FY25 guide). US tax reform provides sustained benefit.
Buyback Pace Acceleration
Q: "$1.9B Q3 buyback is well above prior pace. What's the framework — opportunistic at $475 or sustained?"
— David Roman, Goldman Sachs
A: "In line with our capital allocation priorities, during the quarter we used $1.9 billion of cash to repurchase approximately 4 million of Intuitive Surgical, Inc. shares."
— Jamie Samath, CFO
Assessment: Opportunistic at depressed prices. Pace likely moderates as stock recovers.
US Utilization Inflection Sustainability
Q: "US utilization +4% — best in years. Is this sustainable through 2026?"
— Anthony Petrone, Mizuho
A: "Increased growth in US da Vinci utilization reflected strong Q3 procedure growth and a higher mix of da Vinci V in the installed base, where utilization is higher than Xi."
— Jamie Samath, CFO
Assessment: Utilization +4% should sustain through 2026 as dV5 mix grows. Structural tailwind.
SP Stapler Initial Launch Feedback
Q: "SP stapler initial colorectal + thoracic feedback — what's the early traction?"
— Travis Steed, BofA
A: "At Intuitive 360, I had a conversation with a longtime da Vinci thoracic surgeon about his initial experience using SP on about 40 patients. He was enthusiastic both about the reduction in length of stay and also his first few cases of using the SP stapler."
— David Rosa, CEO
Assessment: Early traction positive. SP stapler is the unlock for colorectal + thoracic SP adoption.
What They're NOT Saying
- dV5 specific gross margin %
- OUS dV5 placement target for FY25 exit
- 2026 tax rate guidance specifics
- China tender volume specific outlook
- ASC market opportunity sizing
- Force feedback adoption rate specifics
Market Reaction
- Pre-print: Stock ~$475; YTD -5%; trailing 12M -8%; ~50x FY25 EPS
- After-hours: +5-7% on beat + 3rd raise
- Oct 22 close: ~$501, +5.5% (+$26); volume 1.8x average
Reaction validates the operational acceleration narrative. Multiple PT raises 10-15% to $530-590 range.
Street Perspective
Debate: Is the 3rd Consecutive Raise Conservative or Honest?
Bull view: Conservative — management's H2 visibility supports continued upside; FY25 likely lands at high end.
Bear view: Honest — fast growth pulls forward orders; FY26 deceleration possible.
Our take: Lean bull. ISRG historically conservative; raises usually leave room.
Debate: Tax Rate Tailwind Sustainability
Bull view: US tax reform R&D treatment is structural — 21-22% sustainable through FY26+.
Bear view: Q3 had one-time reserve release; forward rate could revert.
Our take: Tax rate likely 21-22% sustainable. Modest EPS uplift through cycle.
Debate: Premium Valuation at 50x+
Bull view: Procedure acceleration + dV5 mix-up + multi-decade growth justify premium.
Bear view: Medical device peers de-rated; ISRG vulnerable if growth decelerates.
Our take: Bull stronger. ISRG's growth profile + recurring revenue 85% defensible at premium.
Model Update Needed
| Item | Prior | New |
|---|---|---|
| FY25 Revenue | $10.0B | $10.1B |
| FY25 EPS | $8.55 | $8.85 |
| FY25 Procedure Growth | 15.5-17% | 17-17.5% |
| FY26 Revenue | $11.7B | $11.8-12.0B |
| FY26 EPS | $10.10 | $10.40 |
| Buyback Pace | $1B/Q | $1.5-2B at depressed prices |
Valuation: PT updated to Base $640 / Bull $720 / Bear $500. Base 60x FY25 EPS $8.85 + multi-year compounder. At $501 post-print: base +28%; bull +44%; bear flat. Up/down ~3:1.
Thesis Scorecard
| Thesis Point | Status |
|---|---|
| Bull #1: Durable procedure growth | Confirmed (+19% accelerating) |
| Bull #2: dV5 platform mix-up | Confirmed (240 placements; 141 trade-ins) |
| Bull #3: OUS expansion | Confirmed (+24%; first dV5 OUS) |
| Bull #4: Utilization inflection | Newly Confirmed (US +4%) |
| Bull #5: Accelerated capital return | Newly Confirmed ($1.9B Q3) |
| Bear #1: GM compression at platform transitions | Mitigating |
| Bear #2: OUS macro headwinds | Confirmed but absorbed |
| Bear #3: Premium valuation | Neutral |
Action: Maintaining Outperform. Multi-quarter compounder thesis broadly strengthened. The print is the cleanest validation of 2025 to date.